Does smoking increase the risk of actinic (solar) keratoses and skin cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Smoking and Skin Cancer Risk: The Evidence

Smoking increases the risk of squamous cell carcinoma (SCC) and actinic keratoses but paradoxically appears to decrease the risk of basal cell carcinoma (BCC) and melanoma, though the latter may reflect detection bias rather than true protection.

Key Findings on Smoking and Specific Skin Cancers

Squamous Cell Carcinoma (SCC)

The evidence consistently demonstrates that smoking elevates SCC risk. A 2020 meta-analysis found current smokers have a 32% increased risk of SCC compared to never-smokers (pooled RR = 1.32,95% CI 1.15-1.52) 1. This association is further supported by a 2024 cross-sectional study showing ever-smokers had nearly double the crude odds of SCC (OR=1.99,95% CI: 1.02-3.88) 2. Interestingly, the 2024 study revealed a non-dose-dependent relationship, with light smokers (≤10 pack-years) showing the highest adjusted odds (AOR=4.90), while heavier smokers showed no significant association 2.

A 2012 systematic review and meta-analysis confirmed smoking significantly increases cutaneous SCC risk (OR 1.52,95% CI 1.15-2.01) 3. The anatomical distribution matters: the UK Million Women Study found current smoking increased limb SCC incidence by 55% (RR=1.55,95% CI 1.41-1.71) but showed minimal association with facial SCC (RR=0.93) 4.

Basal Cell Carcinoma (BCC)

Paradoxically, current smoking is associated with decreased BCC risk. The 2020 meta-analysis showed a 15% reduction (pooled RR = 0.85,95% CI 0.75-0.96) 1, while the UK Million Women Study found a 20% decrease (RR=0.80,95% CI 0.78-0.82) 4. This inverse association was particularly pronounced for limb lesions (RR=0.72) 4.

Important caveat: This apparent protective effect likely represents detection bias rather than true biological protection. A 2017 Australian prospective study noted that current smokers underwent fewer skin examinations and procedures than never-smokers, creating greater detection opportunities among non-smokers 5. The 2012 meta-analysis found no significant association between smoking and BCC overall (OR 0.95% CI 0.82-1.09) 3.

Melanoma

Current smoking shows an inverse association with melanoma (pooled RR = 0.72,95% CI 0.64-0.82) 1, but this finding should be interpreted with the same detection bias concerns as BCC.

Actinic Keratoses (Solar Keratoses)

The 2024 cross-sectional study found no marked association between tobacco pack-years and actinic keratoses when controlling for confounding factors like age 2. However, the established guidelines note that sunscreen use has been demonstrated to reduce solar keratoses, which are precursors to SCC 6.

Clinical Implications

Risk Stratification

When counseling patients about skin cancer risk, recognize that:

  • Smokers face elevated SCC risk, particularly on sun-exposed limbs
  • The relationship is not clearly dose-dependent, with even light smoking conferring increased risk
  • Former smokers show similar risks to never-smokers for all skin cancer types 1
  • UV exposure remains the principal environmental risk factor 7, 8, 9

Synergistic Effects

Laboratory evidence demonstrates toxic synergy between solar radiation and cigarette smoke on keratinocytes. Combined exposure to cigarette smoke extract and simulated solar radiation caused an 81% decrease in cell viability, far exceeding either exposure alone 10. This suggests smoking may amplify UV-induced skin damage.

Surveillance Considerations

Patients with actinic keratoses have substantial skin cancer risk regardless of smoking status. A 2023 Medicare study found 28.5% of patients with AKs developed skin cancer within 5 years, with elevated risks for SCC (aHR 2.63), BCC (aHR 1.85), and melanoma (aHR 1.67) compared to controls 11.

Practical Recommendations

For current smokers:

  • Emphasize smoking cessation as part of comprehensive skin cancer prevention
  • Focus on SCC risk elevation, particularly for sun-exposed areas
  • Maintain standard UV protection counseling (sunscreen, protective clothing, avoiding midday sun 10 AM-4 PM) 7, 9
  • Do not assume lower BCC/melanoma rates represent true protection—maintain vigilant surveillance

For all patients:

  • UV exposure remains the dominant modifiable risk factor 7, 8
  • Fair-skinned individuals with red/blond hair who burn easily remain highest risk regardless of smoking status 7, 9
  • Sunscreen use prevents SCC and actinic keratoses 6

The evidence clearly establishes smoking as an independent risk factor for SCC and actinic keratoses, while the apparent inverse associations with BCC and melanoma likely reflect surveillance bias rather than biological protection.

References

Related Questions

What is the recommended treatment for an adult with advanced actinic keratosis involving adnexal structures?
What is the recommended treatment for actinic keratosis?
What is the most effective treatment for extensive actinic keratoses in an 89-year-old male with hypertension?
How should I evaluate and manage a patient with bilateral forearm burning, allodynia, and paresthesia after iodinated contrast exposure and recent amiodarone (Cordarone) discontinuation, who also has actinic keratoses on the forearms?
What is the first‑line topical therapy (cream) for actinic keratosis in an adult patient?
A patient received one dose of Shingrix (recombinant zoster vaccine) 10 years ago; what should be done now?
Can hydroxyzine be initiated as the first‑line treatment in a 79‑year‑old Asian woman?
Can letrozole be taken concurrently with a vitamin B complex supplement?
What is the effect of letrozole on endometriosis in a reproductive‑age woman planning IVF, and how should it be incorporated into the ovarian stimulation protocol?
What is the recommended dosing schedule for sertraline in elderly patients, including starting dose, titration, maximum dose, and adjustments for hepatic or renal impairment?
For a patient with opioid use disorder on low-dose methadone maintenance (e.g., 20–30 mg daily) who also has Hashimoto thyroiditis on levothyroxine, intermittent nephropathy, and hypertension treated with telmisartan and dapagliflozin, how long does it take for brain opioid receptors and dopamine function to return to near‑normal, and after discontinuing methadone after four years, how long will physical and mental symptoms persist?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.